BGB-16673 is an investigational oral BTK-targeted chimeric degradation activation compound. The Food and Drug Administration (FDA) has granted Fast Track designation to BGB-16673 for the treatment of ...

For BTK inhibitor selection in frontline CLL treatment, age, risk profile, and long-term sequencing strategy influence ...

We thank Gang Lv and colleagues for the response to our study.1 We agree that minimal residual disease (MRD) monitoring could help to optimise the treatment of mantle-cell lymphoma with ibrutinib and ...

Only about 1% of patients with chronic lymphocytic leukemia (CLL) developed an invasive fungal infection while on a Bruton’s tyrosine kinase (BTK) inhibitor, investigators found. A new analysis of ...

Mantle cell lymphoma (MCL) relapsed or refractory in patients who have previously received at least two lines of systemic therapy including a Bruton tyrosine kinase (BTK) inhibitor; or Chronic ...

Nurix Therapeutics, Inc. presented promising preclinical data at the AACR 2025 Annual Meeting, showcasing their innovative targeted protein degradation medicines aimed at addressing various cancers, ...

Jaypirca is a targeted therapy for CLL and other specific cancers. It is known as a Bruton’s tyrosine kinase inhibitor (BTK inhibitor). BTK is an enzyme that helps certain types of cancer cells grow.

SAN DIEGO -- An investigational Bruton's tyrosine kinase (BTK) inhibitor significantly improved hidradenitis suppurativa (HS) disease status in a randomized, placebo-controlled trial reported here.

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. He's also a ...